Home › Kanser sa Ovary
Pag-aaral pangklinika para sa Kanser sa Ovary na nagre-recruit sa U.S.
269 pag-aaral para sa Kanser sa Ovary ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX90 pag-aaral
- New York City, NY75 pag-aaral
- Boston, MA62 pag-aaral
- Los Angeles, CA53 pag-aaral
- Nashville, TN50 pag-aaral
- Arlington, VA47 pag-aaral
- Philadelphia, PA47 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO37 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX33 pag-aaral
- Pittsburgh, PA32 pag-aaral
- Dallas, TX31 pag-aaral
- Queens, NY30 pag-aaral
- Atlanta, GA29 pag-aaral
- Seattle, WA29 pag-aaral
- Cleveland, OH29 pag-aaral
- Oklahoma City, OK29 pag-aaral
- Durham, NC28 pag-aaral
- Portland, OR28 pag-aaral
- Detroit, MI28 pag-aaral
- Baldwin Park, CA27 pag-aaral
- Rochester, MN27 pag-aaral
- Washington, DC25 pag-aaral
- Grand Rapids, MI25 pag-aaral
- Birmingham, AL25 pag-aaral
- Orlando, FL24 pag-aaral
- San Diego, CA24 pag-aaral
- Miami, FL24 pag-aaral
- Minneapolis, MN23 pag-aaral
- Baltimore, MD23 pag-aaral
- Aurora, CO23 pag-aaral
- San Francisco, CA20 pag-aaral
- New Haven, CT20 pag-aaral
- Tampa, FL20 pag-aaral
- Fort Worth, TX19 pag-aaral
- Mountain View, CA19 pag-aaral
- Edison, NJ19 pag-aaral
- Salt Lake City, UT19 pag-aaral
- Indianapolis, IN18 pag-aaral
Ayos sa estado
- Alabama29 pag-aaral
- Alaska7 pag-aaral
- Arizona25 pag-aaral
- Arkansas10 pag-aaral
- California109 pag-aaral
- Colorado44 pag-aaral
- Connecticut27 pag-aaral
- Delaware5 pag-aaral
- District of Columbia8 pag-aaral
- Florida83 pag-aaral
- Georgia34 pag-aaral
- Hawaii7 pag-aaral
- Idaho4 pag-aaral
- Illinois48 pag-aaral
- Indiana23 pag-aaral
- Iowa11 pag-aaral
- Kansas12 pag-aaral
- Kentucky22 pag-aaral
- Louisiana20 pag-aaral
- Maine8 pag-aaral
- Maryland40 pag-aaral
- Massachusetts70 pag-aaral
- Michigan51 pag-aaral
- Minnesota51 pag-aaral
- Mississippi6 pag-aaral
- Missouri41 pag-aaral
- Montana10 pag-aaral
- Nebraska16 pag-aaral
- Nevada10 pag-aaral
- New Hampshire4 pag-aaral
- New Jersey39 pag-aaral
- New Mexico14 pag-aaral
- New York101 pag-aaral
- North Carolina48 pag-aaral
- North Dakota7 pag-aaral
- Ohio68 pag-aaral
- Oklahoma32 pag-aaral
- Oregon37 pag-aaral
- Pennsylvania73 pag-aaral
- Rhode Island16 pag-aaral
- South Carolina16 pag-aaral
- South Dakota16 pag-aaral
- Tennessee56 pag-aaral
- Texas128 pag-aaral
- Utah30 pag-aaral
- Virginia60 pag-aaral
- Washington39 pag-aaral
- West Virginia11 pag-aaral
- Wisconsin30 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07360314DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kababaihan · Na-update Nob 13, 2026 · NCT06964009Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07001748Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Nagre-recruitObservasyonal na pag-aaral
Edad 2 hanggang 100 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01950572Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Nagre-recruit
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT05649072Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04847063A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Nagre-recruitPhase 1
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT07664735A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07778498Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT06915025Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT05739981A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06270706Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Nagre-recruitPhase 2
Edad 18 hanggang 72 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01174121Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT06083844Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT05564377A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 10, 2026 · NCT07743164A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 10, 2026 · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 10, 2026 · NCT07318558Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Nob 10, 2026 · NCT07718854Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06580314Phase 1 Study of VT-101 in Advanced Ovarian Cancer
Nagre-recruitPhase 1
Edad 18 hanggang 99 · Kababaihan · Na-update Nob 9, 2026 · NCT07905677A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 9, 2026 · NCT07546500A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kababaihan · Na-update Nob 9, 2026 · NCT04516447Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 6, 2026 · NCT07851025Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Nob 6, 2026 · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
Edad 35 hanggang 50 · Kababaihan · Na-update Nob 6, 2026 · NCT04251052Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.